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Abstract
Syndecan-1 forms complexes with growth factors and their cognate receptors in the cell membrane. We have previously
reported a tubulin-mediated translocation of syndecan-1 to the nucleus. The transport route and functional significance of
nuclear syndecan-1 is still incompletely understood. Here we investigate the sub-cellular distribution of syndecan-1, FGF-2,
FGFR-1 and heparanase in malignant mesenchymal tumor cells, and explore the possibility of their coordinated
translocation to the nucleus. To elucidate a structural requirement for this nuclear transport, we have transfected cells with
a syndecan-1/EGFP construct or with a short truncated version containing only the tubulin binding RMKKK sequence. The
sub-cellular distribution of the EGFP fusion proteins was monitored by fluorescence microscopy. Our data indicate that
syndecan-1, FGF-2 and heparanase co-localize in the nucleus, whereas FGFR-1 is enriched mainly in the perinuclear area.
Overexpression of syndecan-1 results in increased nuclear accumulation of FGF-2, demonstrating the functional importance
of syndecan-1 for this nuclear transport. Interestingly, exogenously added FGF-2 does not follow the route taken by
endogenous FGF-2. Furthermore, we prove that the RMKKK sequence of syndecan-1 is necessary and sufficient for nuclear
translocation, acting as a nuclear localization signal, and the Arginine residue is vital for this localization. We conclude that
syndecan-1 and FGF-2, but not FGFR-1 share a common transport route and co-localize with heparanase in the nucleus, and
this transport is mediated by the RMKKK motif in syndecan-1. Our study opens a new perspective in the proteoglycan field
and provides more evidence of nuclear interactions of syndecan-1.
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Introduction
Proteoglycans (PGs) are highly sulfated macromolecules, whose
protein cores bear covalently attached glycosaminoglycan (GAG)
chains. Cell surface heparan sulfate proteoglycans (HSPGs) are
present in most cells of both vertebrates and invertebrates. At the
cell surface the GAG chains interact with many ligands such as
growth factors (GFs), cytokines, adhesion molecules etc. [1,2], and
they are essential modulators of cellular signaling in embryonic
development and tumorigenesis [3,4]. The transmembrane HSPG
syndecan-1 is the prototype member of the syndecan family, and it
participates in assembling signaling complexes by presenting GFs
to growth factor receptors (GFRs) [5]. The ability of basic
fibroblast growth factor (FGF-2) to bind to fibroblast growth factor
receptor-1 (FGFR-1) has been proven to depend largely on the
presence of heparan sulfate (HS), which interacts with both FGF-2
and FGFR-1, stabilizing the ligand/receptor complex [6,7,8,9,10].
The HS chains can be degraded by heparanase through
enzymatic cleavage [11] and in this way the HSPG-bound GFs
can be liberated. Experimental studies show that cleavage of the
HS chain may generate oligosaccharide sequences, which can
either inhibit or potentiate the effect of the GFs [12]. Notably, HS
is not only a substrate for, but also a regulator of heparanase
uptake [13], and syndecan-1 in turn is able to regulate the
biological activity of heparanase [14].
Traditionally, syndecan-1 has been thought to exert its effect in
signaling at the level of the cell membrane. However, we have
previously shown a regulated nuclear translocation and co-
localization of syndecan-1 with tubulin in the mitotic spindle
[15]. We detected prominent nuclear syndecan-1 not only in
malignant mesothelioma but also in various adenocarcinomas and
in neuroblastoma cells. Similar but weaker nuclear staining was
seen in different benign cells of mesenchymal origin [15]. This was
the first evidence for the nuclear translocation of the whole
syndecan-1 molecule. The HS chains of PGs have long been
known to be present in the nuclear compartment of various
normal and transformed cells concurrently with inhibition of cell
growth [16,17,18,19]. Apart from syndecan-1, other HSPGs can
also be present in the nucleus [20], e.g. syndecan-2 [21,22] and
glypican-1 [23].
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of syndecan-1 is still incompletely understood. Mounting evidence
suggests a similar nuclear accumulation of GFs [24,25], and their
receptors [26,27,28]. Exogenously added FGF-2 has been shown
to internalize and translocate to the nucleus in proliferating cells,
whereas in quiescent cells it remains mainly cytoplasmic [29]. The
nuclear and nucleolar translocation of FGF-2 and FGFR-1 occurs
around the restriction point of the cell cycle in mid-late G1 phase,
suggesting a controlled nuclear entry [30,31]. Moreover, the
efficiency of the nuclear FGF-2 translocation is increased in the
presence of heparin [32].
In our previous work, double staining experiments clearly
demonstrated that syndecan-1 is structurally linked to the
intracellular microtubule system in all phases of cell division,
and that inhibition of microtubule polymerization by vinblastine
treatment hampers the nuclear translocation of syndecan-1 [15].
As syndecan-1 can bind both GFs and their GFRs, we aimed in
this study to investigate the possibility of a regulated co-
translocation of syndecan-1, FGF-2 and FGFR-1. Furthermore,
we hypothesize that the syndecan-1/tubulin complex may not only
act as a vehicle for the transport of GFs to the cell nucleus, but it
may also constitute a functional entity in an intracrine route,
which operates independently from the cell surface receptor
function. Our experiments are designed to clarify the translocation
of the syndecan-1/FGF-2/FGFR-1 complex, and the structural
requirement for the nuclear transport of syndecan-1.
Materials and Methods
Cell lines and cell culture conditions
Three cell lines of mesenchymal origin were used in this study.
The STAV malignant mesothelioma cells were generally grown in
RPMI 1640 medium containing 25 mM HEPES (GIBCO, Grand
Island, NY, USA) and 2 mM L-Glutamine. The STAV-AB cell
sub-line was supplemented with 10% human AB serum and
displayed epithelial differentiation, while the STAV-FCS cell sub-
line was supplemented with 5% fetal bovine serum (FBS) and 5%
calf serum (CS) to achieve a fibroblast-like morphology [33]. The
B6FS human fibrosarcoma cells [34] were grown in RPMI 1640 +
GlutaMAX
TM-1 (GIBCO) supplemented with 10% FBS and
20 mg/ml Gentamicin (GIBCO). All cells were cultured in 75 cm
2
Tissue Culture Flasks (Sarstedt, Newton, NC, USA) in humidified
5% (v/v) CO2 at 37uC and culture medium was changed twice a
week. The STAV-AB cells show a low endogenous syndecan-1
expression level on the cell surface [35], while the B6FS cells do
not express syndecan-1 [36].
Sub-cellular localization of syndecan-1, endogenous
FGF-2, heparanase and FGFR-1
The sub-cellular distributions of syndecan-1, heparanase, FGF-
2 and FGFR-1 were examined by immunocytochemical analysis
and subsequent confocal laser microscopy. Cells were seeded onto
Superfrost Plus microscope slides and allowed to adhere for 6–
48 hours before they were fixed with 3% paraformaldehyde at
37uC for 10 minutes, and then permeabilized with 0.1–0.5%
Triton X-100 (Sigma, Steinheim, Germany) at 37uC for 15
minutes. For the tubulin depolymerization experiments, cells were
fixed in ice-cold methanol for 10 minutes, rehydrated in PBS and
taken directly for immunocytochemistry.
For visualizationof cell membrane syndecan-1and HS reactivity,
the cells were not permeabilized in order to keep the integrity of the
cell membrane. Non-specific binding was blocked with 3% goat
serum (DAKO A/S, Giostrup, Denmark) for 30 minutes; thereafter
the primary antibody was added (Table 1). Slides were incubated
overnight in a humidified chamber at 4uC, followed by 30 minutes
of incubation with fluorescent secondary antibodies (Table 2) in
darkness at room temperature. The slides were counterstained with
1 mg/L Bisbenzimide H33342 (FLUKA, Steinheim, Germany),
and mounted in DAKO Fluorescent Mounting Medium (DAKO,
Via Real Carpiteria, CA, USA).
Double labeling was performed by simultaneous incubation
with the respective primary antibodies. Negative controls were
used, either with affinity purified mouse or goat IgG (Table 1) or,
in the case of CD138, by preincubating the antibody with the
syndecan-1 epitope.
A large number of primary and secondary antibody combina-
tions were tested and the corresponding isotype controls were
always included to allow background subtraction. We performed
single label experiments to exclude over-bleeding between the
channels.
Nuclear complex co-immunoprecipitation and
immunoblotting
Nuclear complex co-immunoprecipitation (Co-IP) was carried
out using the Nuclear Complex Co-IP Kit (Active Motif Europe,
Rixensart, Belgium) according to the manufacturer’s instruc-
tions. Briefly, nuclear extracts of sub-confluent cells were
prepared 24–36 hours after seeding of cells stably transfected
with syndecan-1/EGFP constructs or those transfected with just
EGFP vector. Protein concentrations were determined by the
Bradford method using bovine serum albumin (BSA) as a
standard. For Co-IP, 100 mg of each nuclear extract was reacted
Table 1. Primary antibodies used.
No. Antigen Clone Dilution Company/catalogue no.
1 Syndecan-1(CD138), mouse monoclonal IgG1 B-B4 1:4 Serotec MCA681 H
2 Syndecan-1, goat polyclonal - 1:20 Santa Cruz sc-7099
3 FGF-2, mouse monoclonal IgG2a MC-GF1 1:4 Serotec MCA1400G
4 FGF-2, goat polyclonal N-19 1:20 Santa Cruz sc-1390
5 FGFR-1, mouse monoclonal IgM VBS1 1:20 Biogenesis
6 HS, mouse monoclonal IgM 10E4 1:200 Seikagaku 370255
7 Heparanase, mouse monoclonal mAB 130 1:400 InSight Ltd.
8 Heparanase, rabbit polyclonal pAB 733 1:10 Vlodavsky et. al.
9 a-tubulin, mouse monoclonal IgG1 B-5-1-2 1:2000 Sigma T5168
doi:10.1371/journal.pone.0007346.t001
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syndecan-1 (C-20, sc-7099, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA). The coupled protein/antibody com-
plexes were adsorbed onto protein G Sepharose
TM Fast Flow
beads (GE Healthcare Life Sciences, Uppsala, Sweden). The
protein/antibody complex beads were re-suspended in TBS
buffer. The immunoprecipitated proteins were released from the
beads by boiling at 95–100uC for 3–5 minutes and spinning
briefly to collect supernatants. The nuclear precipitates from
equal amounts of control and sample proteins were blotted
directly to a nitrocellulose membrane, using the Minifold II Slot
Blot System (Schleicher & Schuell, Inc., Keene, NH, USA.), and
followed by immunoblotting with a mouse anti-human FGF-2
monoclonal antibody (MCA1400G, AbD Serotec Ltd., Oxford,
UK). The secondary antibody was an ECL
TM Peroxidase-
labeled anti-mouse antibody (NA931VS, GE Healthcare Life
Sciences, Uppsala, Sweden). Chemiluminescence detection was
performed using Western Lightening
TM Chemiluminescence
Reagent Plus (NEL 104, Perkin Elmer LAS, Inc., Waltham,,MA,
USA). Chemiluminescence signals were recorded with a charge-
coupled device camera (FluorChemHS P ,A l p h a I n n o t e c h ,S a n
Leandro, CA, USA).
Confocal laser microscopy
For detailed visualization of the distribution of antibody
reactivity, confocal laser microscopy was used. This was performed
with a Leica TCS NT confocal laser scanning microscope
equipped with an ArKr laser, permitting the detection of signals
from the fluorochromes with emission wavelengths at 488 nm and
568 nm. Scanning was performed using a 6361.2 NA objective
lens and higher magnifications with zoom function. Images were
obtained by scanning in the XY direction with a focal depth of
0.3 mm and were then processed with Adobe Photoshop software.
For each experiment the excitation and sensitivity of the detector
were adjusted so that the signals were normalized to the
corresponding negative controls. The instrument settings were
adjusted to omit non-specific reactivity and over-bleeding.
Effect of drugs interfering with microtubule assembly
and cell cycle progression on the sub-cellular distribution
of syndecan-1, FGF-2 and FGFR-1
Vinblastine promotes depolymerization of tubulin and its
redistribution into paracrystalline inclusion bodies. To depolymer-
ize tubulin structures, cells were exposed to 10 mM of vinblastine
(VelbeH - Eli Lilly Sweden AB, Stockholm, Sweden) for 2 hours, as
an established way to demonstrate tubulin-dependent transport
[37]. This was followed by immunocytochemical staining for FGF-
2, syndecan-1 (CD 138) and FGFR-1. All experiments were
performed in at least triplicate. Double staining was performed for
tubulin (mouse monoclonal IgG1, detected by goat anti-mouse IgG
(H+L), F(ab’)2 Alexa 488) and FGF-2 (goat polyclonal, detected by
donkey anti-goat IgG (H+L) Alexa 568), or syndecan-1 (goat
polyclonal, detected by donkey anti-goat IgG (H+L) Alexa 568).
Double staining was also performed with FGFR-1 (mouse
monoclonal IgM, detected by goat anti-mouse IgM Alexa 488)
and tubulin (mouse monoclonal IgG1, detected by goat anti-mouse
IgG1 Alexa 568).
Doxorubicin is a chemotherapeutic agent known to cause
cellular damage via a number of mechanisms including inhibition
of topoisomerase II, nucleotide intercalation, free radical forma-
tion and inhibition of DNA replication. Doxorubicin treatment
results in G2 arrest and interferes with cell cycle progression by
sustaining the G2 arrest after DNA damage [38]. Mesothelioma
cells were exposed to 1.2 mg/ml Doxorubicin (AdriamycinH,
Pharmacia & Upjohn, Stockholm, Sweden) for 48 hours, followed
by immunocytochemical staining with mouse monoclonal IgG1
against syndecan-1, detected by goat anti-mouse IgG (H+L),
F(ab’)2 Alexa 488.
Sub-cellular localization of exogenously added FGF-2 in
the mesothelioma cells
The sub-cellular fate of exogenously added, fluorescence-tagged
FGF-2 was monitored in vitro. For this purpose recombinant
human FGF-2 (R&D Systems, Minneapolis, MN, USA) was
labeled with Alexa FluorH 488 (A10235, Molecular Probes, Inc.,
Leiden, The Netherlands), according to the instructions of the
manufacturers. Based on our previous data on the mitogenic effect
of FGF-2 on mesothelioma cells, the concentration of FGF-2 used
ranged from 5–50 ng/mL. The observation times were 16 h, 24 h
and 42 h after seeding. In parallel, double staining was performed
for syndecan-1 (goat polyclonal, detected by donkey anti-goat IgG
(H+L) Alexa 568) and the endogenous FGF-2 (mouse monoclonal
IgG2a, detected by goat anti-mouse IgG (H+L), F(ab’)2 Alexa 488).
Transfection of cells with full-length and truncated
syndecan-1 constructs and detection of nuclear
accumulation of syndecan-1
To further clarify the possible role of syndecan-1, we have
transfected the cells with a syndecan-1/EGFP construct, or a
truncated variant, coding only for the RMKKK sequence, which
corresponds to a hypothesized nuclear localization signal of
syndecan-1. The syndecan-1/EGFP constructs were prepared by
Table 2. Secondary antibodies used.
No. Preparation Dilution Company/catalogue #
I Goat a-mouse IgG (H+L), F(ab’)2 Alexa 568 1:800 Molecular Probes A11019
II Donkey a-goat IgG (H+L) Alexa 568 1:800 Molecular Probes A11057
III Goat a-mouse IgG (H+L), F(ab’)2 Alexa 488 1:800 Molecular Probes A11017
IV Goat a-mouse IgM Alexa 488 1:800 Molecular Probes A21042
V Goat a-mouse IgM Alexa 568 1:800 Molecular Probes A21043
VI Goat a-mouse IgG1 Alexa 568 1:800 Molecular Probes A21124
VII Goat a-rabbit IgG (H+L) highly cross-adsorbed, Alexa 488 1:800 Molecular Probes A11034
VIII Goat a-mouse IgG (H+L) highly cross-adsorbed, Alexa 568 1:1600 Molecular Probes A11031
Blocking solutions consisted of 3% goat or donkey serum, or 1% BSA in PBS.
doi:10.1371/journal.pone.0007346.t002
Nuclear Syndecan-1 and FGF-2
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7346Szila ´k Labor Ltd, (Szeged, Hungary) and the pEGFP-N1 vector,
used as a negative control, was purchased from BD Biosciences,
(Clontech, Palo Alto, CA, USA). The construct of human
syndecan-1 was cloned on a HindIII – BamHI fragment into
pEGFP-N1 plasmid in-frame with the N-terminal end of EGFP.
The correct DNA sequence of this construct was verified by DNA
sequencing. The plasmids were amplified in E. coli and purified
with EndoFree Plasmid Maxi Kit (QIAGEN GmbH, Hilden,
Germany). Their purity was determined by spectrophotometry
and agarose gel electrophoresis.
Cells were transfected with the constructs above, using Effectene
Transfection Reagent (QIAGEN GmbH, Hilden, Germany).
Optimization of the transfection was carried out according to the
manufacturer’s guidelines. Briefly, about 2610
5 cells were seeded
into 6-well plates and incubated for 24 hours to reach 40–80% of
confluence at the time of transfection. Transient transfections were
performed using 0.4 mg DNA and a DNA/Effectene ratio of 1:25.
The presence of the functional syndecan-1/EGFP fusion protein
was verified by immunocytochemical analysis with antibodies
against syndecan-1 (CD-138) and HS (mouse monoclonal IgM,
clone 10E4, Seikagaku Corporation, Tokyo, Japan) using confocal
microscopy, as described above. The appearance and sub-cellular
distribution of the newly synthesized syndecan-1 were evaluated at
various time points (6, 12, 24, 48, and 72 hours) after transfection
using a fluorescence microscope (Leica DM IRBE, Openlab 3.0.4
software) to follow the EGFP-positive cells.
Site directed mutational analysis of the RMKKK sequence
The RMKKK sequence of syndecan-1 corresponding to Arg -
Met –Lys – Lys - Lys was subjected to site directed mutagenesis by
GenScript Corporation (NJ, USA) to generate three mutants.
These were mutant 1, Ala - Met - Leu - Lys – Lys (AMLKK);
mutant 2, Ala - Met - Lys - Leu – Lys (AMKLK); and mutant 3,
Arg – Met -Leu - Leu – Lys (RMLLK).
Cells were transfected with the RMKKK construct, or the
mutants 1–3, according to the transfection protocol described
above, and their fate was subsequently followed by confocal laser
microscopy.
Results
Sub-cellular localization of syndecan-1, heparanase,
FGF-2 and FGFR-1
The sub-cellular distributions of syndecan-1, heparanase, FGF-
2 and FGFR-1 were examined by immunocytochemistry.
Syndecan-1 showed maximal intensity in the cell nuclei, nucleoli
and/or in the perinuclear area (Figure 1B, E and H,
respectively). The relative distribution of syndecan-1 between
these locations, however, varied somewhat. Apart from the nuclear
reactivity, cytoplasmic and cell membrane staining at the cell-cell
contact sites were also clearly detected in malignant cells
(Figure 1, Figure S1). Double staining with antibody specific
for FGF-2 revealed similar distinct nuclear and nucleolar
reactivities (Figure 1A). The nuclear reactivity of FGF-2 and
syndecan-1 strictly co-localized (Figure 1C). Also heparanase
(Figure 1G) showed co-localization with syndecan-1 in the
nucleus (Figure 1H, I), suggesting the presence of a functional
entity. In contrast, FGFR-1 (Figure 1D), known to form signaling
complexes with FGF-2, was found only in the cytoplasm with
maximal intensity in the perinuclear area, where it co-localized
with syndecan-1 (Figure 1E, F). Notably, there was no FGFR-1
reactivity present in the nucleus of mesothelioma cells. The
staining intensity at these locations varied, but the staining pattern
was reproducible. The cells only displayed background levels of
fluorescence when stained with corresponding isotype controls
(Figure 1J-L).
Crude nuclear extracts from these cells also showed immuno-
reactivity to both syndecan-1 and FGF-2. The latter was increased
considerably, following upregulation of syndecan-1 by transfection
(data not shown). When syndecan-1 was specifically immunopre-
cipitated, FGF-2 was also found in the precipitate. The amount of
co-precipitated nuclear FGF-2 increased when syndecan-1 was
overexpressed (Figure 2), demonstrating that syndecan-1 is
needed for this nuclear translocation.
Effect of drugs interfering with microtubule assembly
and cell cycle progression on the nuclear translocation of
syndecan-1
Treatment with vinblastine resulted in depolymerization of
tubulin, which then precipitated into paracrystalline inclusion
bodies (Figure 3A–C), whereas untreated cells showed the
characteristic fibrillar tubulin structure (Figure S2). Double
labeling experiments showed that both FGF-2 (Figure 3A) and
syndecan-1 (Figure 3B) strictly co-localized with the depolymer-
ized tubulin; furthermore, that tubulin depolymerization com-
pletely hampered the nuclear translocation of both syndecan-1
and FGF-2. In contrast, FGFR-1 was not associated with tubulin,
and its distribution was not affected by vinblastine treatment
(Figure 3C). FGFR-1 and tubulin had distinct cytoplasmic
localization and were completely independent of each other.
These results show that the transport route of FGFR-1 differs from
that of syndecan-1 and FGF-2, which both associate and co-
precipitate with the depolymerized tubulin. Doxorubicin, known
to arrest cells in the G2 phase of the cell cycle, almost completely
inhibited the nuclear transport of syndecan-1. When cells were
exposed to doxorubicin from the time of cell seeding, sporadic
weak nuclear syndecan-1 staining could be observed in single
scattered cells only (Figure 3E). In contrast, the untreated cells
showed distinct nuclear staining of syndecan-1 (Figure 3D).
The sub-cellular localization of exogenous FGF-2
In order to see whether externally administered FGF-2 would
translocate to the nucleus via a tubulin-syndecan-1 mediated
transport route, Alexa-labeled FGF-2 was added exogenously to
the cell cultures. The intracellular distribution of Alexa-labeled
FGF-2 was restricted to the cytoplasm of mesothelioma STAV-AB
cells up to 42 hours after seeding (Figure 4A). This time scale was
chosen based on our previous observation on the time course of
the nuclear translocation of syndecan-1 [15]. In parallel, double
staining (Figure 4B) revealed a substantial pool of endogenous
FGF-2 in the nucleus, whereas syndecan-1 remained cytoplasmic.
Transport route and sub-cellular localization of newly
synthesized syndecan-1
The newly synthesized syndecan-1/EGFP and RMKKK/EGFP
fusion proteins revealed signals of varying intensity and distinct sub-
cellular distributions by fluorescence microscopy (Figure 5). The
specificity of the signal was confirmed by immunocytochemical
staining, using the CD138 antibody (Figure 6), which specifically
recognizes the extracellular domain of syndecan-1, and verifies that
functional syndecan-1 is being synthesized.
In the transfected B6FS cells, detectable amount of syndecan-1/
EGFP fluorescence was seen already 6 hours after transfection, and
the expression patternchanged over time. Cytoplasmic fluorescence
was seen at all time points, but after 6–12 hours there was a clear
perinuclear accumulation and after 24 hours syndecan-1 appeared
in the nucleus (Figure 5B). Notably, the most prominent nuclear
Nuclear Syndecan-1 and FGF-2
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that this pentapeptide may act as a putative nuclear localization
signal for syndecan-1 (Figure 5B). Such nuclear localization
appeared in approximately 60% of the transfected cells, whereas no
nuclear localization was observed in the corresponding EGFP
controls (Figure 5B). Similar sub-cellular distribution was also seen
in the other studied cell types, i.e. the STAV-AB and STAV-FCS
malignant mesothelioma cell sub-lines (Figure S3). Accumulation
of syndecan-1/EGFP in the cell membrane could only be observed
in few scattered cells (Figure 6A, D). The EGFP fluorescence
coincided with the syndecan-1 ectodomain (Figure 6B, C).
Furthermore, cell surface reactivity to HS could be detected by
the 10E4 antibody in the syndecan-1/EGFP transfected cells. HS
co-localized with EGFP florescence at the cell membrane, revealing
that the newly synthesized syndecan-1/EGFP fusion protein also
carried HS chains (Figure 6D–F).
Mutational analysis of the RMKKK sequence
In cells transfected to express the RMKKK mutant 1 (Ala -M e t-
Leu- Lys – Lys,AMLKK)or mutant 2 (Ala -M e t-L y s-Leu–L y s ,
Figure 1. FGF-2 and heparanase, but not FGFR-1 co-localize with syndecan-1 in the nuclear compartment of mesothelioma cells.
Immunocytochemical staining of the STAV-AB cells for FGF-2 (A) or syndecan-1 (B) showed distinct nuclear and nucleolar localization. Merged images
revealed a complete co-localization of FGF-2 and syndecan-1 (C) inside the nuclear envelope. FGFR-1 showed prominent perinuclear staining (D), and
syndecan-1(E) showed onlya partial co-localizationwithFGFR-1inthe perinuclear area (F).Strong nuclear reactivity was alsodetectedforheparanase(G),
and syndecan-1 (H), with a clear nuclear co-localization (I). The corresponding isotype controls are shown as (J), (K) and (L). Bar =10mm. Antibodies used:
(A) 3+ III. (B) and (E) 2+ II. (D) 5+ IV. (G) 8+ VII. (H) 1+I (Tables 1 and 2).
doi:10.1371/journal.pone.0007346.g001
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portion ofcells with a nuclear positivity for EGFP signalwas reduced
by up to 50% compared to wide type RMKKK (Figure 7). These
EGFP fusion proteins were evenly distributed over the entire cell,
without accumulation in any sub-cellular compartment. The
replacement of two of the three lysines with leucines, but retention
of the arginine, inmutant 3 (Arg – Met -Leu - Leu –L y s ,R M L L K ) ,
did not significantly affect the nuclear localization. These results
indicate the essential role of the arginine residue for the nuclear
translocation of the RMKKK motif.
Discussion
Malignant mesothelioma and fibrosarcoma are aggressive
tumors of mesenchymal origin, and they express a characteristic
PG profile, in which syndecan-2 and -4 are the main cell-surface
PGs [35,36]. Syndecan-1 is less abundant at the surface of
mesothelioma cells, and the most prominent syndecan-1 reactivity
is seen in the nucleus and in the mitotic spindle during mitosis.
Moreover, the accumulation of syndecan-1 in the nucleus is
tubulin-dependent and precedes the cell membrane reactivity,
which is seen later when the culture becomes confluent. This
phenomenon has been observed in a series of both benign and
malignant cells [15].
The co-localization of syndecan-1 with heparanase in cell nuclei
suggests a simultaneous mechanism for the turnover of HS,
indicating a regulatory importance of the nuclear syndecan-1.
Similar nuclear accumulation occurs for growth factors, in
particular FGF-2. In the mesothelioma cells we could detect a
nuclear pool of syndecan-1 and FGF-2, whereas FGFR-1
remained exclusively perinuclear. In contrast to other cell types,
this receptor never reached the nuclear compartment
[25,26,27,39]. Our results not only add to the growing literature
Figure 2. Syndecan-1 and FGF-2 co-immunoprecipitate in the
nucleus of the STAV-AB cells. Co-IP and immunoblotting were
performed on nuclear extracts of sub-confluent cultures of the STAV-AB
cells, stably transfected with syndecan-1/EGFP construct or EGFP vector,
as described in ‘‘Materials and Methods’’. Nuclear extract (100 mg) was
incubated with 3 mg of syndecan-1 antibody, or with no antibody
(negative control). The nuclear precipitates from equal amounts of
control and sample proteins were slot-blotted onto a nitrocellulose
membrane and then probed with antibody to FGF-2. A crude nuclear
extract from syndecan-1/EGFP transfected cells was used as positive
control. Co-IP using a specific antibody to syndecan-1 also pulled down
FGF-2, as compared to the negative control. The amount of FGF-2 was
higher in nuclear extracts from syndecan-1 overexpressing cells,
compared to the EGFP control.
doi:10.1371/journal.pone.0007346.g002
Figure 3. Effects of drugs interfering with microtubule assembly and cell cycle progression. The sub-cellular localizations of FGF-2 (A),
syndecan-1 (B) and FGFR-1 (C) in the STAV-AB cells were detected after depolymerization of tubulin by vinblastine shown as co-localized
paracrystalline structures (yellow crystals). Double staining was performed with tubulin (green) and either FGF-2 (red) (A) or syndecan-1 (red) (B), and
both revealed strict co-localization of these components (yellow crystals, A, B). No co-localization of FGFR-1 (green) and tubulin (red) is detected (C),
indicating a different transport route. Untreated STAV-FCS mesothelioma cells showed strong nuclear reactivity for syndecan-1 (D). Doxorubicin
almost completely inhibited the nuclear transport of syndecan-1 in these cells (E).
doi:10.1371/journal.pone.0007346.g003
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FGF-2 [24,40], but also identify a tubulin-mediated transport
route for both syndecan-1 and FGF-2.
Immunoprecipitation experiments indicate that the co-localiza-
tion of FGF-2 with syndecan-1 is associated with a physical
interaction between the two proteins (Figure 2). We have recently
proved by FACS analysis that syndecan-1 protein levels are
increased 2-3 fold in these stable transfectants [36]. Our present
data show that by overexpressing syndecan-1 the amount of
nuclear FGF-2 increased approximately 2-fold, which provides
evidence that syndecan-1 is needed for the nuclear transport of
FGF-2. The presence of a greater amount of FGF-2 in the crude
nuclear extract indicates that only part of the nuclear FGF-2 is
bound to syndecan-1. This finding suggests that there also are
other syndecan-1 independent routes for FGF-2 transport to the
nucleus. Tubulin depolymerization prevents the nuclear transport
of FGF-2 and syndecan-1 (Figure 3A, B), and the fact that both
components co-localize with the depolymerized tubulin indicates
stable associations between them. They thus seem to share a
common tubulin-dependent transport mechanism. In contrast, no
nuclear localization (Figure 1D) or co-localization with tubulin
was observed for FGFR-1 (Figure 3C) pointing toward a
divergent transport route for this molecule.
We have previously shown nuclear syndecan-1 in many other
cell types besides malignant mesothelioma, including benign
mesothelial cells, normal dermal fibroblasts, endothelial cells,
adenocarcinomas and neuroblastoma cells [15]. In the present
study, we show that the cytoplasmic RMKKK sequence of
syndecan-1 is acting as a nuclear localization signal. This sequence
corresponds to the characteristic short sequence of positively
charged amino acids like lysine (K) and arginine (R) that defines a
nuclear protein [41,42]. It is located in the highly conserved C1
domain of syndecan-1, also known to be involved in the linkage to
several cytoskeletal proteins, including tubulin, cortactin and ezrin
[3]. Our findings show that this short motif of syndecan-1 is both
necessary and sufficient for the nuclear translocation of a protein,
as shown here fused to EGFP (Figure 5). Transfection with the
RMKKK/EGFP construct results in a rapid accumulation of the
fusion protein in the cell nucleus, whereas no such nuclear
accumulation is observed in the control EGFP-transfected cells.
Furthermore, replacement of the one arginine is sufficient to
substantially decrease the nuclear accumulation of the mutated
fusion proteins. The mutants 1 and 2 share a common arginine
mutation and give a dramatic decrease of nuclear translocation,
which indicates that arginine is most crucial for this function
(Figure 7). However, the syndecan-1/EGFP construct, carrying
the EGFP on the cytoplasmic tail, translocated to the nucleus
much less efficiently than the native syndecan-1 or the RMKKK/
EGFP construct. This indicates that the C-terminal region of
syndecan-1 is important for the tubulin-mediated nuclear
transport.
The EGFP fluorescence co-localizes both with newly synthe-
sized syndecan-1 protein and HS at the cell membrane, revealing
that the newly synthesized syndecan-1/EGFP fusion protein also
carries HS chains (Figure 6), which is important for its GF
binding capacity. To what extent the HS chains are themselves
important for the nuclear translocation process is still an open and
challenging question. Chen L et al have recently shown that
heparanase overexpression or addition of recombinant heparansae
decreases the nuclear syndecan-1 in a concentration-dependent
manner, suggesting that the translocation is dependent to a
significant extent upon the HS chains [43].
It has been suggested that the interaction of syndecan-1 with GFs
on the cell surface may assist the internalization and intracellular
trafficking of these factors. This mechanism is not completely
elucidated, but several lines of evidence indicate the importance of
HSPG in this process. Furthermore, GFs likeFGF-2 and PDGF can
act by triggering second messenger systems in addition to their
effects on gene transcription [44]. Studies show that internalized
FGF-2 survives longer periods of time in cells expressing HSPGs
than in HSPG-deficient cells [45]. The majority of GF/GFR
complexes on the cell surface get internalized and degraded in
lysosomes, perhaps as part of the receptor-turnover pathway (for
review see [46,47]). The HSPG/GF complex might serve as a
reservoir for GFs protecting them from degradation and allowing
later entrance into the nucleus. However, such transport of
exogenous FGF-2 from the cell surface to the nucleus could not
be verified in the mesothelioma cells (Figure 4A). The finding that
exogenously added GF never reached the nucleus in detectable
amounts, contradicts the idea that this is a major route for FGF-2
present in the nucleus. In contrast, a substantial pool of endogenous
FGF-2 is detected in the nucleus at the same time point by a parallel
immunostaining (Figure 4B), suggesting an independent intracrine
route,besidesa tubulin/syndecan-1mediated nucleartranslocation.
Figure 4. The sub-cellular localization of exogenously added FGF-2 differs from that of endogenous FGF2. In the STAV-AB cells, no
nuclear accumulation of exogenously added Alexa 488-labeled FGF-2 could be observed 42 hours after seeding (A). In parallel, immunocytochemical
staining (B) showed the presence of an endogenous pool of FGF-2 (green) in the nucleus, whereas syndecan-1 (red) remained cytoplasmic at this time
point.
doi:10.1371/journal.pone.0007346.g004
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7346Figure 5. Schematic representation and sub-cellular localization of the syndecan-1/EGFP fusion proteins. The whole syndecan-1
molecule was fused to EGFP, whereas the truncated RMKKK/EGFP construct contained only the tubulin binding RMKKK motif, which acts as a nuclear
localization signal. The figure indicates where in the cytoplasmic domain of syndecan-1 the RMKKK sequence is located (A). The sub-cellular
localization of the syndecan-1/EGFP fusion proteins, after transfection into the B6FS cells were detected by fluorescence microscopy (B). EGFP-
transfected control cells revealed only cytoplasmic reactivity at various time points (24–72 h) (B, left column). Distinct nuclear localization was seen in
the RMKKK/EGFP transfected cells (B, middle column), whereas the syndecan-1/EGFP fusion protein revealed faint nuclear, cytoplasmic and focal cell
membrane reactivities (B, right column).
doi:10.1371/journal.pone.0007346.g005
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PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7346Figure 6. Immunocytochemical detection of the syndecan-1 ectodomain and HS chains in syndecan-1/EGFP transfectants. In the
STAV-AB mesothelioma cells, cell membrane EGFP fluorescence appeared only in scattered cells 48 hours after transfection with syndecan-1/EGFP
construct (A, D). The immunocytochemical detection of the syndecan-1 ectodomain (CD-138, Mouse monoclonal IgG1, detected by Goat anti-mouse
IgG1 Alexa 568) is shown in (B), and the HS chains (mouse monoclonal IgM, clone 10E4, detected by Goat a-mouse IgM Alexa 568) in (E). The
syndecan-1/EGFP fusion protein co-localized with the total amount of syndecan-1(C) and to some extent with the total amount of HS (F). Bar
=20mm.
doi:10.1371/journal.pone.0007346.g006
Figure 7. Site directed mutational analysis of the RMKKK sequence in B6FS cells. Mutants 1 and 2, but not mutant 3 showed a significant
decrease in the proportion of cells with nuclear localization of the respective EGFP construct, when compared to the wild type RMKKK transfectants.
Asterisks denote a statistically significant difference from RMKKK. Error bars show standard errors of the mean (SEM) of three independent
experiments. Mutations are highlighted in color in the scheme of the mutants.
doi:10.1371/journal.pone.0007346.g007
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nuclear FGF-2 in the crude nuclear extract and also co-
immunoprecipitated together with the ectodomain of syndecan-1
(Figure 2), thereby emphasizing the role of syndecan-1 for this
nuclear translocation.
Whether syndecan-1 follows an intracrine route or passes the
cell membrane can not be answered from the present experimental
results. The fact that syndecan-1 is seen in the nucleus before it
accumulates in the cell membrane [15] to some extent supports
the hypothesis of an intracrine loop. Since there is a strict co-
localization of both N- and C-terminal portions of the syndecan-1
core protein with the HS side chains, the nuclear syndecan-1
seems to be the entire HSPG, which therefore must have been
processed by the Golgi apparatus for HS modification before
being transported to the nucleus.
It is plausible that this PG may be directed to different cellular
compartments at different situations. Syndecan-1 gives faint
immunocytochemical staining at the cell surface of the mesothe-
lioma cells, detectable amounts being seen only at cell confluence.
It may be that in the confluent cultures the shedding of syndecan-1
decreases, allowing it to accumulate on the cell surface [15]. The
finding that FGF-2 and syndecan-1 often, but not always, co-
localize in the nucleus, and that their expression levels vary during
the experiments, also leaves the possibility of alternative routes for
the nuclear translocation of these two components. This variability
may also depend on a dynamic molecular switch consisting of
subsequent association and dissociation events, where the activity
of the HS moieties is modulated by the co-localizing heparanase.
Once in the nucleus, however, syndecan-1 may well bind GFs, as
shown by their tight co-localization. Furthermore, the activity of
the heparanase may counteract the formation of GFs/syndecan-1
complexes, thereby regulating their possible functions.
The presence of syndecan-1 inside the nucleus raises many
challenging questions remaining to be elucidated, including the
nuclear targets of syndecan-1 and their possible downstream
effects. Studies on such effects of nuclear syndecan-1 have been
initiated in our laboratory.
Supporting Information
Figure S1 Characteristic staining pattern of syndecan-1 in
malignant cells. Immunocytochemical staining of syndecan-1 by
CD138 antibody was performed in MCF-7 breast cancer (A, B),
WART adenocarcinoma (C) and HTB-11 neuroblastoma (D) cells.
Distinct nuclear syndecan-1 reactivity was seen in all cells. In
addition to nuclear staining, a prominent perinuclear staining was
seen in (B), distinct cell membrane staining at the cell-cell contact
sites in (C), and cytoplasmic and cell membrane positivity in (D).
Found at: doi:10.1371/journal.pone.0007346.s001 (1.48 MB TIF)
Figure S2 Tubulin structure in the mesothelioma cells. Sub-
confluent the STAV-AB malignant mesothelioma cells were
stained with primary antibody to a-tubulin (mouse monoclonal
IgG1, Sigma T5168), and detected by green fluorescent secondary
antibody (goat anti-mouse IgG (H+L), F(ab’)2 Alexa 488,
Molecular Probes A11017). Typical fibrillar tubulin structure
was seen in the mesothelioma cells without vinblastine treatment.
Found at: doi:10.1371/journal.pone.0007346.s002 (0.59 MB TIF)
Figure S3 Sub-cellular localization of syndecan-1/EGFP fusion
proteins in the STAV-AB and STAV-FCS mesothelioma cell lines.
The EGFP-transfected control cells displayed only cytoplasmic
reactivity at various time points (24–72 h) (left column). Distinct
nuclear localization was seen in the RMKKK/EGFP transfected
cells (middle column), whereas the syndecan-1/EGFP fusion
protein revealed faint nuclear, cytoplasmic and focal cell membrane
reactivities (right column).
Found at: doi:10.1371/journal.pone.0007346.s003 (0.83 MB TIF)
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